TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04170101

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: moderate NMB
Description: 0,6 mg/kg LBW rocuronium is used to facilitate intubation, not followed by an infusion or extra bolus.
Study: NCT04773730

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior transversus abdominus plane block
Description: Twenty mL of bupivacaine 0.25% will be injected in the plane between the transverses abdominus muscle and the fascia deep to the internal oblique muscle on each side
Study: NCT05144048

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient setting
Description: These women stay at the maternity unit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient setting
Description: These women leave the maternity unit
Study: NCT04773730

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block type 2
Description: Twenty mL of bupivacaine 0.25% will be injected on the posterior surface of quadrates lumborum muscle on each side
Study: NCT05667207

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care microscopy and dipstick guided management
Description: GPs will be encouraged to apply the following diagnosis and treatment algorithm (figure 1) to consenting women, taking their preferences into account:~1. If POCTs are positive for bacteria by microscopy and/or for erythrocytes by dipsticks the GP issues, at his/her own clinical judgement, a delayed or immediate prescription for an antibiotic.10 In the MicUTI intervention, delayed prescription is defined as issuing an antibiotic prescription with the advice to take the medication only when symptoms do not improve or worsen in 48 hours.~2. If POCTs are negative for bacteria and erythrocytes, the GP advises for self-help remedies according to guidelines and to do without antibiotics Study specific training in point-of-care microscopy will be provided to intervention practices.
Study: NCT05507502

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccination administration
Description: There will be approximately 40 participants who consent; they will be randomized in a 1:1 manner to receiving the influenza vaccination during their heart failure hospitalization versus receiving the vaccine during their first follow-up in the heart failure clinic.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccination administration
Description: There will be approximately 40 participants who consent; they will be randomized in a 1:1 manner to receiving the influenza vaccination during their heart failure hospitalization versus receiving the vaccine during their first follow-up in the heart failure clinic.
Study: NCT05451394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROAF
Description: Use of the method Ressource Optimisation of Armed Forces (ROAF). 6 one-hour workshops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: 6 one-hour workshops on cognitive process
Study: NCT05610475

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood cell analysis, blood gas surveillance, chest radiograph and echocardiography
Description: Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: blood cell analysis, blood gas surveillance, chest radiograph and echocardiography
Description: Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
Study: NCT03309514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intracerebral microinjections
Description: Stereotactic delivery of cell suspension into basal ganglia structures
Study: NCT04819477

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fact box
Description: All physicians surveyed receive a fact box with numerical information on the benefits and harms of chest CT as a screening method.~In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.
Study: NCT05967078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExerG
Description: The intervention for primary end users (PEU, (patients)) includes the performance of two training rounds with the device. The first round includes a predefined training sequence, whereas the second round is a training sequence defined by the therapist.~For the secondary end user group (SEU, (therapists)), there are two study visits. At their first visit they get an introduction and training on how to use the system. At their second visit, SEU will have to prepare the device (switch on hard- and software) and guide the patient through the training.
Study: NCT06345222

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prolotherapy
Description: The Modified Prolotherapy technique was applied in the study and 0.5cc 5% Dextrose injection was applied per injection to the tendon entesis and/or tendon of the patient's non-rheumatic chronic, myoskeletal knee-induced, pain-inducing sensation. The follow-up period was determined as 1 month after the last injection. The ligaments to be injected within the scope of the research (context knee pain) were determined as Lateral Collateral Ligament (LCL), AnteroLateral Collateral Ligament (ALL), Medial Collateral Ligament (MCL), Pes Anserius and Patellar Ligament.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: The Modified Prolotherapy technique was applied in the study and 0.5cc 5% Dextrose injection was applied per injection to the tendon entesis and/or tendon of the patient's non-rheumatic chronic, myoskeletal knee-induced, pain-inducing sensation. The follow-up period was determined as 1 month after the last injection. The ligaments to be injected within the scope of the research (context knee pain) were determined as Lateral Collateral Ligament (LCL), AnteroLateral Collateral Ligament (ALL), Medial Collateral Ligament (MCL), Pes Anserius and Patellar Ligament.
Study: NCT06050356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H107e
Description: Participants will receive two i.m. injections of 20 µg unadjuvanted H107e on Day 1 and Day 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAF®10b
Description: Participants will receive two i.m. injections of CAF®10b (full adjuvant dose) on Day 1 and Day 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H107e/CAF®10b - low adjuvant dose
Description: Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (low adjuvant dose) on Day 1 and Day 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H107e/CAF®10b - full adjuvant dose
Description: Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H107e/CAF®10b - full adjuvant dose
Description: Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose intranasal H107e
Description: Participants will receive one i.n. administration of 15 µg H107e (low dose intranasal H107e) on Day 85

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full dose intranasal H107e
Description: Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 85

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H107e/CAF®10b
Description: Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H107e/CAF®10b
Description: Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: i.m. placebo
Description: Participants will receive two i.m. injections of placebo on Day 1 and Day 29

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: i.m. placebo
Description: Participants will receive two i.m. injections of placebo on Day 1 and Day 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Participants will receive one i.d. injection of BCG on Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: Participants will receive one i.d. injection of BCG on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i.d. placebo
Description: Participants will receive one i.d. injection of placebo on Day 1
Study: NCT04819477

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fact box
Description: All physicians surveyed receive a fact box with numerical information on the benefits and harms of chest CT as a screening method.~In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cates plot
Description: In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.
Study: NCT06364202

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut Butter
Description: 2 tablespoons of peanut butter
Study: NCT06380972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polycaprolactone (PCL) Based Facial Injectable
Description: Polycaprolactone (PCL) Based Facial Injectable
Study: NCT05086666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: In Phase 1b study, subjects will receive continuous twice daily dosing in 21-day cycles (no matter if missed doses or delays exist), with pre-set dose cohorts of 80 mg BID and 120 mg BID.~In Phase 2, subjects will receive continuous twice daily dosing in 21-day cycles with the RP2D or other doses as determined by the investigator and sponsor.
Study: NCT05059925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured gym activities
Description: Planned and structured activities such as Strength training~* Dumbbell Exercises (1kg with 2 sets of 10 repetitions)~* Sit-ups (2 sets of 10 repetitions)~* Stair climbing, (2 sets of 10 stairs up and down)~* Squat (2 sets of 10 repetitions) Flexibility training • Tai chi (Peng. Lu, chi, an Tsai, lieh, chou, Kao (Hold each posture for 20 seconds)) • Pilates (Breathing., Shoulder bridge, Leg lifts (Hold each pose for 20 seconds)) • Stretching techniques (Neck stretch, Shoulder stretch, Side stretch Hold each stretch for 20 seconds)).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional aerobic activities
Description: Activities performed such as~* Treadmill Time: 10 minutes Intensity: 60 to 80% of target heart rate~* Cycle ergometer Time: 10 minutes Intensity: 60 to 80% of target heart rate~* Elliptical exercises Time: 10 minutes Intensity: 60 to 80% of target heart rate
Study: NCT05576428

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and exercise
Description: diet and exercise in patients of NAFLD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Description: diet and exercise in patients of NAFLD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC with diet and exercise
Description: NAC with diet and exercise in patients of NAFLD
Study: NCT05156515

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-THP-APN09
Description: APN09, nanobody targeting PD-L1, labeled with PET radio-nuclide (68Ga) will be used as a molecular imaging tracer for PET/CT scan.
Study: NCT05072587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based diet with no oxysterols
Description: This group will be given 3 prepared plant-based meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard ADA Diet (SADA)
Description: This group will be given 3 prepared meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
Study: NCT04783103

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil
Description: 3 weeks home use

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil
Description: 3 weeks home use
Study: NCT06319651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Limb Resistance Band Exercises
Description: * Extending thighs~* Closing thighs~* Opening thighs~* Bending thighs~* Bending ankles~* Ankle opening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Phase 1 cardiac rehabilitation
Description: Routine Phase 1 cardiac rehabilitation only.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Phase 1 cardiac rehabilitation
Description: Routine Phase 1 cardiac rehabilitation only.
Study: NCT06302725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal self sampling detecting HPV
Description: IMIDs patients who are not up to date with CCS be included into the study to perform a vaginal self-screening (VSS) A positive VSS will be confirmed by a standard HPV test and management of the results of standard HPV test or VSS will be performed as planned following HAS guidelines. For women with a positive VSS, follow-up results (HPV test and cytology, biopsy, etc.) will be collected according to the usual procedures of the screening facility and in accordance with the recommendations of the Health authorities
Study: NCT04912713

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stress group
Description: This group will perform the MAST stress protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: This group will perform the MAST control protocol
Study: NCT06355856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNN.22.17.036
Description: Apply twice daily to the affected area and around it.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10573048700
Description: Apply twice daily to the affected area and around it.
Study: NCT05127928

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Vitamin C and vitamin E
Description: Antioxidant supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration
Study: NCT04714762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eMOM GDM application
Description: Participants in the intervention group will use the eMOM GDM -application one week/month.~eMOM GDM application includes:~* continuous glucose monitor (CGM, Medtronic)~* diet (digital food tracker) (min 3 days during one application week)~* heartrate, stress and physical activity with the wrist-worn activity tracker (Vivosmart 3)~* weight measured once a week~The sensors can be worn and the application used during the whole pregnancy (if a mother is interested in)
Study: NCT06593652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teen Intervene - Adolescent Only
Description: Teen Intervene (TI) is delivered over two or three, 45- to 60-minute sessions (2 teen sessions +/- 1 caregiver session) to reduce youth substance use, increase motivation for abstinence, and promote use of existing coping strategies. TI is an adolescent-appropriate adaptation of motivational enhancement therapy (MET), and includes a discussion of readiness to change, goal setting, personal feedback, a functional analysis of substance use, and a review of coping skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Intervene with Caregiver Session
Description: Teen Intervene (TI) is delivered over two or three, 45- to 60-minute sessions (2 teen sessions +/- 1 caregiver session) to reduce youth substance use, increase motivation for abstinence, and promote use of existing coping strategies. TI is an adolescent-appropriate adaptation of motivational enhancement therapy (MET), and includes a discussion of readiness to change, goal setting, personal feedback, a functional analysis of substance use, and a review of coping skills. In this condition, the caregiver session will address caregiver expectations around youth substance use and strategies for promoting positive youth behavior change including reduced substance use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check Up
Description: Family Check-Up Online (FCU-O) is a self-paced, parent-driven, fully HIPAA compliant online version of the Family Check-Up (FCU), a brief intervention that integrates assessment, motivation-enhancement, and skill building to help parents effectively manage behavior and build positive relationships with their children aged 2-17 in order to reduce emotional and behavioral problems among youth.
Study: NCT04660773

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NB UVB phototherapy
Description: ultraviolet phototherapy sessions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: oral medication
Study: NCT06621576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM2002 injection
Description: Eligible subjects under general anesthesia will undergo CABG surgery. After completing the distal anastomosis, 5mg of HM2002 injection solution drawn into a 1 ml syringe will be administered via multi-point injection using an OT needle or insulin needle (preferably a 30G needle). The injections will be spaced approximately 1 cm apart, with no more than 30 injection points, into the myocardium at the edge of the MI area (with obvious infarcts) or the area of the diseased coronary artery branches (without obvious infarcts) through the epicardium.
Study: NCT06731725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DayDrop®
Description: The patient will administer 1 to 2 instillations each time it is necessary (at least 2 times a day) and will record it in their data collection notebook.
Study: NCT06730152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeChat Intervention Based on the IMB Model
Description: The intervention group would undergo a six-week intervention program. Researchers promoted a public WeChat account to the intervention group, and participants received the intervention by following the account. They automatically received pushed articles or videos, providing them with relevant knowledge about overcoming smartphone addiction. Furthermore, they would be motivated to quit their addiction through real-life cases of smartphone addiction etc., in addition to some practical skills of overcoming.
Study: NCT05698537

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG
Description: EEG registration performed in PwE to confirm epilepsy diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging
Description: Neuroimaging performed in PwE to diagnose epilepsy etiology

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood samples from both PwE and controls will be collected to measure full blood count, IgM and IgG antibodies to parasitic antigens including Taenia solium, Toxoplasma gondii and Plasmodium falciparum, to perform ELISA for HIV1 and HIV2, to measure HIV viral load and to conduct an emmel test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood samples from both PwE and controls will be collected to measure full blood count, IgM and IgG antibodies to parasitic antigens including Taenia solium, Toxoplasma gondii and Plasmodium falciparum, to perform ELISA for HIV1 and HIV2, to measure HIV viral load and to conduct an emmel test.

Intervention type: OTHER
Intervention: Risk factor questionnaire
Description: Both PwE and control subjects will complete a structured questionnaire on a wide range of potential risk factors present before the onset of the epilepsy.

Intervention type: OTHER
Intervention: Risk factor questionnaire
Description: Both PwE and control subjects will complete a structured questionnaire on a wide range of potential risk factors present before the onset of the epilepsy.
Study: NCT05699876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 6 MG
Description: melatonin will be administered orally preoperatively as premedication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: melatonin will be administered orally preoperatively as premedication
Study: NCT05583045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive Leaf Tea
Description: Olive leaf tea (individual tea bags provided to participants with instructions of preparation)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle behavior change program (LBC)
Description: Lifestyle behavior change program as defined by America Diabetes Association on Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers(Association 2022)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle behavior change program (LBC)
Description: Lifestyle behavior change program as defined by America Diabetes Association on Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers(Association 2022)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tea
Description: Placebo tea containing 2,6g cellulose and a caramel coloring
Study: NCT05455086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarette Smoking
Description: Receive 1 puff of tobacco flavored protonated e-liquid
Study: NCT05163730

Intervention type: DEVICE
Group type: OTHER
Intervention: COVID-19/ Flu A&B Rapid Panel
Description: Rapid Diagnostic Device